Nitrogen, Other Than Nitro Or Nitroso, Bonded Indirectly To Phosphorus Patents (Class 514/114)
-
Patent number: 8802656Abstract: A new pharmaceutical composition is disclosed comprising a purified phospholipid-selective and/for nonselective non-steroidal, anti-inflammatory drug associated complex and methods for making and using same. A screening method for identifying compounds that form phospholipid associated complexes is also disclosed.Type: GrantFiled: October 12, 2005Date of Patent: August 12, 2014Assignee: The Board of Regents of the University of Texas SystemInventor: Lenard Lichtenberger
-
Patent number: 8802123Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.Type: GrantFiled: June 8, 2012Date of Patent: August 12, 2014Assignees: Universite de Geneve, Ecole Polytechnique Federale de LausanneInventors: Pierre Descouts, Björn-Owe Aronsson, Michael Grätzel, Carine Viornery, Peter Péchy
-
Publication number: 20140221317Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: March 18, 2014Publication date: August 7, 2014Applicant: Allergan, Inc.Inventors: PHONG X. NGUYEN, TODD M. HEIDELBAUGH, John R. Cappiello
-
Publication number: 20140213557Abstract: The present invention relates to novel active compound combinations comprising, firstly, a known herbicide selected from the group consisting of glyphosate, glufosinate and glufosinate-ammonium and, secondly, at least one known fungicidally active compound, which combination is highly suitable for controlling unwanted phytopathogenic fungi, in particular soya bean rust. Particular preference is given to using these mixtures on transgenic plants resistant to the herbicides mentioned.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Bayer CropScience AGInventors: Klaus STENZEL, Markus Dollinger, Peter Dahmen, Ulrike Wachendorff-Neumann, Isolde Häuser-Hahn, Marie-Claire Grosjean, Bernard Marc Leroux, Haruko Sawada, Hiroyuki Hadano, Jean-Marie Gouot, Christian Scherb
-
Publication number: 20140206652Abstract: The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: March 20, 2014Publication date: July 24, 2014Applicant: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
-
Publication number: 20140205669Abstract: Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.Type: ApplicationFiled: November 26, 2013Publication date: July 24, 2014Applicant: THE PENN STATE RESEARCH FOUNDATIONInventors: Brian M. Barth, Mark Kester, James H. Adair, Todd E. Fox
-
Patent number: 8778838Abstract: The present invention relates to aqueous concentrate formulations for plant protection comprising: 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and water; wherein the pH-value of the formulation is below 6.Type: GrantFiled: August 26, 2010Date of Patent: July 15, 2014Assignee: BASF SEInventors: Michael Krapp, Wolfgang Gregori, Sven Adam, Klaus Kolb, Juergen Jakob, Bernd Sievernich, Joerg Steuerwald, Steven Bowe, Joseph Zawierucha, Rex Liebl
-
Patent number: 8778914Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.Type: GrantFiled: August 24, 2010Date of Patent: July 15, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Katrin Hochdoerffer
-
Publication number: 20140193376Abstract: The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are disclosed. One aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC mobilization. The invention also relates to methods of using these combinations of CXCR4 antagonists and S1PR1 modulator agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells, for example for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating a symptom associated with such diseases, disabilities or conditions.Type: ApplicationFiled: June 18, 2012Publication date: July 10, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Leonard I Zon, Owen J. Tamplin
-
Publication number: 20140194392Abstract: A drug screening method is disclosed. The drug screening method includes steps of screening a compound library to obtain a first group of compounds capable of binding to a wild type target; screening the first group of compounds to obtain a second group of compounds capable of binding to a mutant site of a mutant target; analyzing characteristics of binding sites of the wild type target and the mutant type target to obtain physico-chemical properties of the binding sites; identifying a candidate from the second group of compounds according to the physico-chemical properties of the binding site; and performing a bio-assay on inhibitory activity of the candidate.Type: ApplicationFiled: April 29, 2013Publication date: July 10, 2014Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventors: Jinn-Moon Yang, Kai-Cheng Hsu
-
Publication number: 20140187516Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: NOVARTIS AGInventors: Craig BOULTON, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
-
Publication number: 20140179636Abstract: Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.Type: ApplicationFiled: December 6, 2013Publication date: June 26, 2014Applicant: NOVARTIS AGInventors: Vivian Georgousis, Wei-Qin Tong
-
Publication number: 20140171393Abstract: The present invention relates to novel aromatic thio derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: December 9, 2013Publication date: June 19, 2014Applicant: Allergan, Inc.Inventors: Phong X. Nguyen, John R. Cappiello, Todd M. Heidelbaugh
-
Patent number: 8754066Abstract: The present invention relates to novel phenoxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: February 20, 2013Date of Patent: June 17, 2014Assignee: Allergan, Inc.Inventors: Wenkui K. Fang, Liming Wang, Ken Chow, Evelyn G. Corpuz, Wha-Bin Im
-
Publication number: 20140162964Abstract: Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases.Type: ApplicationFiled: December 2, 2013Publication date: June 12, 2014Applicant: NOVARTIS AGInventors: Volker Brinkmann, Nicole Kaneider, Christian J. Wiedermann
-
Publication number: 20140155355Abstract: The invention provides novel compounds of formulae I and II: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).Type: ApplicationFiled: April 29, 2013Publication date: June 5, 2014Inventor: Jenrin Discovery
-
Patent number: 8741875Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: February 11, 2013Date of Patent: June 3, 2014Assignee: Allergan, Inc.Inventors: Todd M. Heidelbaugh, Phong X. Nguyen, John Cappiello
-
Publication number: 20140148415Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.Type: ApplicationFiled: January 31, 2014Publication date: May 29, 2014Applicant: NOVARTIS AGInventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
-
Publication number: 20140135293Abstract: The present invention relates to allene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: ALLERGAN, INC.Inventors: WENKUI K. FANG, Evelyn G. Corpuz, Ken Chow, WhaBin Im
-
Publication number: 20140134270Abstract: A composition contains an agricultural pesticide and an incompletely hydrated water soluble polymer suspended in a liquid medium.Type: ApplicationFiled: January 21, 2014Publication date: May 15, 2014Applicant: Rhodia OperationsInventors: Dan WU, Krish Murthy SHANMUGA, Rajesh GOYAL, Valerio BRAMATI
-
Patent number: 8716267Abstract: The present invention relates to novel bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: April 13, 2012Date of Patent: May 6, 2014Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
-
Publication number: 20140113883Abstract: An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits. This inflammatory reaction also limits the extent of the effect of the injected medication to a localized area. A lecithin and aqueous glucose and sodium chloride based biphasic injection dosage formulation is disclosed which is applicable to subcutaneous, intramuscular, and intravenous administration. Additionally, a program based approach to the treatment of subcutaneous fat deposits which includes injections of this formulation, application of compression garments, diet modification, and exercise is described. The formulation is characterized in that it comprises an adjustable acidifying agent to set pH, an antioxidant, a sclerosing agent, and a stabilizer.Type: ApplicationFiled: May 24, 2013Publication date: April 24, 2014Inventor: James Robert DeLuze
-
Patent number: 8703745Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: February 21, 2013Date of Patent: April 22, 2014Assignee: Allergan, Inc.Inventors: Todd M. Heidelbaugh, Phong X. Nguyen
-
Patent number: 8703752Abstract: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate (activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving a tissue dysfunction linked to deregulation of said pathway.Type: GrantFiled: January 22, 2004Date of Patent: April 22, 2014Assignee: Centre National de la Recherche ScientifiqueInventors: Martial Ruat, Elisabeth Traiffort, Hélène Faure
-
Publication number: 20140107078Abstract: The invention relates to hypophosphorous acid derivatives of formula (I) wherein —X is H or OH, —R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising -0-(CH2)n—COOH; —S—(CH2)n—COOH; —NH—(CH2)n—COOH; -0-(CH,R?)—COOH; —O—(CH2)n—OH; OR?, —R? being a C1-C3 alkyl radical; —OH; —COOH; halogen, particularly —F, —CI, —Br, —I, —CF3; —OCF3; —N02; —CH?CH—COOH; —(CH2)n—COOH; O—(CH2)n—P03H2; O—(CF2)n—P03H2; O—(CH2)n—S03H; O—(CH2)n—CONHOH; O—(CH2)n-tetrazol; O—(CH2)n-hydroxyisoxazol—n=1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.Type: ApplicationFiled: May 16, 2012Publication date: April 17, 2014Applicants: UNIVWESITE D"AUVERGNE, UNIVERSITE PARIS DESCARTESInventors: Francine Acher, Jean-Philippe Pin, Cyril Goudet, Alain Eschalier, Jérôme Busserolles, Delphine Rigault, Isabelle Lemasson, Sara Cesarini, Brono Commare
-
Publication number: 20140107079Abstract: The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: Nucites S.A. de C.V.Inventors: Ricardo Abraham De La Cruz Cordero, Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, José Mario Ordóñez Palacios, Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso
-
Publication number: 20140107024Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: Diapin Therapeutics LLCInventor: Zhongmin Ma
-
Publication number: 20140100175Abstract: The present invention provides insecticidal lipids and lipid fractions from fungi of the phylum Ascomycota, together with compositions comprising such lipids and lipid fractions and methods of preparing same. Methods for the biological control of insects, such as phytopathogenic insects, using the lipids and lipid fractions or compositions comprising said lipids optionally together with one or more insecticidal or entomopathogenic agents including entomopathogenic fungi, are also provided.Type: ApplicationFiled: March 26, 2012Publication date: April 10, 2014Applicant: BIOTELLIGA HOLDINGS LIMITEDInventors: Stephen Reynold Ford, Travis Robert Glare
-
Patent number: 8691726Abstract: A synergistic antimicrobial composition containing a glyphosate compound and zinc pyrithione is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition.Type: GrantFiled: December 9, 2011Date of Patent: April 8, 2014Assignee: Dow Global Technologies LLCInventors: Emerentiana Sianawati, Sudhakar Balijepalli
-
Publication number: 20140094437Abstract: This invention relates to a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents that leave undesirable deposits or a sticky after-feel and that has a final viscosity less than 4,000 cps. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a fluorosurfactant of at least 0.001% by weight to prepare a foamable composition or from 0-2.0% to prepare a gel-like composition of a final viscosity less than 4,000 cps, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition or a gel-like composition with a viscosity less than 4,000 cps), and the balance being purified water.Type: ApplicationFiled: October 28, 2013Publication date: April 3, 2014Applicant: DEB WORLDWIDE HEALTHCARE INC.Inventors: MARIA TERESA FERNANDEZ DE CASTRO, BRUCE MICHAEL KOIVISTO
-
Publication number: 20140094444Abstract: The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P1/S1P3 activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P3 expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P3 and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand.Type: ApplicationFiled: March 16, 2012Publication date: April 3, 2014Applicant: University of Virginia Patent FoundationInventors: Edward A. Botchwey, III, Mary J. Laughlin, Kevin R. Lynch, Anusuya Das, Anthony Awojoodu
-
Publication number: 20140066409Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.Type: ApplicationFiled: December 13, 2011Publication date: March 6, 2014Applicants: UNIVERSITÄT KONSTANZ, RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONNInventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
-
Publication number: 20140057878Abstract: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: November 1, 2013Publication date: February 27, 2014Applicant: ALLERGAN, INC.Inventors: Wenkui K. Fang, Liming Wang, Evelyn G. Corpuz, Ken Chow, WhaBin Im
-
Patent number: 8658623Abstract: The present invention relates to novel substituted bicyclic methyl amine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.Type: GrantFiled: July 16, 2013Date of Patent: February 25, 2014Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im
-
Patent number: 8653050Abstract: The present invention relates to novel phenyl bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: July 8, 2013Date of Patent: February 18, 2014Assignee: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im
-
Publication number: 20140045798Abstract: The present invention provides a compound of Formula Ia, wherein R1 is H or phosphate and the double bond is between N1 and C1 or between N2 and C1; R2 is a mitochondrial targeting moiety; R3 an alkyl, alkylaryl, alkylheteroaryl spacer group, a cleavable linker, or absent; R4 is H or an alkyl, aryl, or heteroaryl group; and R5 is alkyl, aryl, or heteroaryl; or N1 C1, and N3 together form a heterocyclic ring containing at least 5 atoms, wherein N1, N3, and R1-R5 are as defined above, or N3 and R5 together form a heterocyclic ring containing at least four atoms; or a pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: October 18, 2013Publication date: February 13, 2014Applicant: Gencia CorporationInventor: Shaharyar Khan
-
Publication number: 20140030366Abstract: Disclosed is a method of treating pain. The method includes administering a lecithin as an active ingredient to a mammal to treat the pain, wherein the pain is caused by at least one of herpes zoster, post-herpetic neuralgia, and diabetic neuropathic pain. The method further includes administering at least one selected from the group consisting of vegetable gel, a vegetable resin, and a synthetic resin, wherein the vegetable gel, vegetable resin, and synthetic resin is selected from the group consisting of aloe gel; a seaweed extract selected from the group consisting of kelp extract, agar extract, and Fucoidan; and a mixture thereof.Type: ApplicationFiled: September 25, 2013Publication date: January 30, 2014Applicant: MOON & J INC.Inventors: Jae-Hoon JUNG, Hyung-Ryong MOON
-
Publication number: 20130345177Abstract: The present invention relates to the use of oleyl phosphocholine (C18:1-PC), or OlPC,for the treatment of mycosis, and especially for the treatment of mycosis such as mycosis caused by pathogens belonging to a genus selected from the group consisting of Candida, Aspergillus, Fusarium, Cryptococcus, Microsporum, Sporothrix, Trichophyton and Scedosporium, for example, Candida albicans, Candida parapsilosis, Candida glabrata, Candida krusei, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, Fusarium solani, Scedosporium prolifacans, Cryptococcus neoformans, Microsporum canis, Sporothrix schenkii, Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus fumigatus, Fusarium oxysporum.Type: ApplicationFiled: February 24, 2012Publication date: December 26, 2013Applicant: DAFRA PHARMA RESEARCH & DEVELOPMENT BVBAInventor: Bruno Jansen
-
Publication number: 20130338108Abstract: The present invention relates to novel phenyl bicyclic methyl amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: July 8, 2013Publication date: December 19, 2013Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im
-
Publication number: 20130338109Abstract: The present invention relates to novel substituted bicyclic methyl amine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.Type: ApplicationFiled: July 16, 2013Publication date: December 19, 2013Applicant: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha-Bin Im
-
Publication number: 20130337046Abstract: The disclosure relates to methods of improving safety, efficacy, or both, of pharmaceutically active aminothiol compounds by delivering them in a thiol-protected form and, preferably intracellularly.Type: ApplicationFiled: June 14, 2013Publication date: December 19, 2013Inventors: Dale M. WALKER, Vernon E. WALKER
-
Patent number: 8609641Abstract: The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.Type: GrantFiled: December 13, 2004Date of Patent: December 17, 2013Assignee: UCB Pharma GmbHInventors: Dieter Scheller, Klaus Hansen
-
Patent number: 8609142Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.Type: GrantFiled: December 13, 2012Date of Patent: December 17, 2013Assignee: BIND Therapeutics, Inc.Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
-
Publication number: 20130323318Abstract: A protein free surfactant composition comprising dipalmitoylphosphatidyl choline (DPPC) and eugenol having a ratio in the range of 10:5 to 4:2 with >99% airway patency in the presence of albumin, for treating acid lung injury, adult respiratory distress syndrome and meconium aspiration syndrome.Type: ApplicationFiled: October 4, 2011Publication date: December 5, 2013Applicant: INDIAN INSTITUTE OF TECHNOLOGYInventors: Rinti Banerjee, Anubhav Kaviratna
-
Publication number: 20130315978Abstract: The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 1,700,000-6,500,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug.Type: ApplicationFiled: February 1, 2012Publication date: November 28, 2013Applicant: NITTO DENKO CORPORATIONInventors: Masato Nishimura, Yoshihiro Iwao, Katsuhiro Okada, Kensuke Matsuoka
-
Publication number: 20130303466Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: November 14, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
-
Publication number: 20130303490Abstract: The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals.Type: ApplicationFiled: December 12, 2011Publication date: November 14, 2013Applicant: Centre National De La Recherche Scientifique-CNRSInventors: Vincent Francois, Pierre Corbeau, Charline Duquenne
-
Publication number: 20130296277Abstract: The present invention relates to pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration and especially ointments for the treatment of leishmaniasis. The present invention further relates to the use of the present ointments for the treatment of parasitic diseases, cancer, or skin diseases and especially ointments for the treatment of leishmaniasis in both humans and animals. Specifically, the present invention relates to pharmaceutical compositions such as ointments and crèmes for the treatment of parasitic diseases, cancer, or skin diseases by topical administration comprising 0.1 to 20 weight %, preferably 0.1 to 10 weight %, more preferably 0.1 to 7 weight %, most preferably 0.5 to 5 weight %, of the pharmaceutical composition oleyl phosphocholine as an active ingredient.Type: ApplicationFiled: January 12, 2012Publication date: November 7, 2013Applicant: DAFRA PHARMA RESEARCH & DEVELOPMENT BVBAInventors: Frans Herwig Jansen, Annie Marie Fortin
-
Patent number: 8569270Abstract: Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R1 is a hydrogen atom or the like; R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like; X is a methylene group which may be substituted with one or two fluorine atoms, or the like; Y is a hydrogen atom or the like; and Z is a halogen atom.Type: GrantFiled: July 8, 2010Date of Patent: October 29, 2013Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yasushi Kohno, Kiyoshi Fujii, Momoko Taru, Keita Miyoshi
-
Patent number: 8568773Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.Type: GrantFiled: June 24, 2009Date of Patent: October 29, 2013Assignee: Enzymotec Ltd.Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled, Yael Richter